Curative Biotechnology Announces U.S. Patent Allowance Strengthening Core Ophthalmology Platform
Industry development with potential relevance for veterinary professionals, companion animal care, and animal health stakeholders.
Digital tools are becoming increasingly important across veterinary medicine, from clinical workflows to client communication and practice operations.
According to the announcement, Curative Biotechnology Announces U.S. Patent Allowance Strengthening Core Ophthalmology Platform. The development is relevant because it reflects how animal health companies, service providers, and technology platforms are responding to changing expectations in veterinary care.
What Was Announced
17/642,610, entitled "Druggable Target to Treat Retinal Degeneration." The U.S. Notice of Allowance follows the Company's previously announced Canadian Notice of Allowance, further expanding its growing global intellectual property portfolio. Curative is the exclusive worldwide licensee of this technology pursuant to a patent license agreement with the National Eye Institute (NEI), part of the National Institutes of Health (NIH).
The invention, developed under the leadership of Dr. Kapil Bharti and his team at the NEI, identifies a novel therapeutic approach for the treatment of retinal degenerative diseases. The allowed claims include methods directed to topical ophthalmic administration of metformin for the treatment of retinal degeneration, including Age-Related Macular Degeneration (AMD), retinal pigment epithelium degeneration, and both Stargardt's disease and Stargardt's-like disease, utilizing pharmaceutical compositions formulated for topical ocular delivery as eye drops, further strengthening the Company's intellectual property protection for its lead metformin-based ophthalmology program.
Why This Matters for Veterinary Professionals
For veterinary professionals, technology announcements matter when they affect efficiency, access to care, diagnostics, reimbursement, or the daily workflow of the clinic.
At the practice level, the most relevant question is whether the development can reduce administrative friction, improve access to information, or support more consistent communication between veterinary teams and clients.
Industry Perspective
The animal health industry continues to move toward more connected, data-driven services for veterinary practices and pet owners.
While individual announcements should be interpreted in the context of their source, they can help veterinary professionals monitor where investment, innovation, and market attention are moving across the animal health sector.
Original announcement: Curative Biotechnology — https://www.globenewswire.com/news-release/2026/07/16/3328338/0/en/curative-biotechnology-announces-u-s-patent-allowance-strengthening-core-ophthalmology-platform.html
Comments
Related Articles
More news
Copyright © 2026 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment